Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects

NCT02469896 is registered in ClinicalTrials.gov with Barrow Neurological Institute as lead sponsor.

NCT NCT02469896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02469896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects
Lead sponsor
Barrow Neurological Institute
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2015
Completion date
July 11, 2018
Enrollment
22 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

als, amyotrophic lateral sclerosis, lou gehrig's disease, motor neuron disease